4.20Open4.20Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover312.96%IV-10.74%PremiumNov 15, 2024Expiry Date4.52Intrinsic Value100Multiplier18DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8316Delta0.1220Gamma0.64Leverage Ratio-0.0135Theta-0.0026Rho-0.53Eff Leverage0.0017Vega
Black Diamond Therapeutics Stock Discussion
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
Black Diamond Therapeutics (Nasdaq: BDTX) announced a corporate restructuring to focus resources on advancing its lead program BDTX-1535into pivotal development for EGFRm NSCLC. The company aims to extend its cash runway into Q2 2026. Key points include:
Anticipates sharing initial Phase 2 data for BDTX-1535 in the frontline setting for EGFRm ...
Next love, right here. 💐🥰🤫🤪
Lots of shorts returned...
No comment yet